Oncomatryx
Oncomatryx is a Spain-based clinical-stage biopharmaceutical company developing antibody-drug conjugates that target Cancer-Associated Fibroblasts in the tumor microenvironment, with lead candidate OMTX705 in Phase Ib/2 trials for metastatic solid tumors.
- Company typePrivate
- Founded2010
- HeadquartersDerio, Spain
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Oncomatryx does
Oncomatryx Biopharma S.A. is a privately held, clinical-stage biopharmaceutical company headquartered in Derio, Spain (Bizkaia Technology Park), with additional R&D operations in Zamudio and San Sebastián (Basque Country, Spain) and Research Triangle Park, North Carolina (via subsidiary Nelum). Founded in 2009–2010 by Dr. Laureano Simón around the discovery that Cancer-Associated Fibroblasts (CAFs) in the tumor stroma drive invasion, drug resistance, and immunosuppression, the company develops a proprietary Antibody-Drug Conjugate (ADC) platform targeting the tumor microenvironment rather than tumor cells directly. The platform integrates three core technology layers: FAP-targeting antibodies with sub-nanomolar affinity, synthetic cytolysin payloads (low molecular weight tubulin polymerization inhibitors that avoid Pgp-mediated multi-drug resistance, acquired via Tube Pharmaceuticals GmbH in 2023), and a proprietary conjugation chemistry designed for bloodstream stability. Lead asset OMTX705 (anti-FAP) is in Phase Ib/2 clinical trials across pancreatic, microsatellite-stable colorectal, NSCLC, and sarcoma indications, with 95 patients dosed and no dose-limiting toxicity observed to date; preclinical assets OMTX703 (anti-endoglin) and OMTX707 (TME-targeting) and a companion diagnostic InvaScan (anti-COL11A1) round out the pipeline.
The company operates a capital-intensive biotech business model. Direct revenues are limited to recurring licensing and co-development income from unnamed international biopharmaceutical partners and non-dilutive European Innovation Council grant funding, with no commercial product sales. Its go-to-market is enterprise-focused: it runs clinical trials directly through a network of seven hospitals in Spain and the USA and pursues licensing and co-development agreements with larger pharmaceutical companies. Capital is sourced primarily from Spanish public investors — CDTI through the Innvierte program, Basque Government and Ekarpen, Kutxa Fundazioa, BBK, and the EIC Accelerator — alongside private family offices, with over €100M raised across rounds in 2015 (€4.5M), 2022 (€15M), 2025 (€25M plus €12.5M EIC), and 2026 (€58M). A March 2026 raise is explicitly financing Oncomatryx's transition into an integrated biopharmaceutical company, including a new Fill & Finish manufacturing plant in Gipuzkoa.
Oncomatryx firmographics
Firmographics- Name
- Oncomatryx
- Legal name
- ONCOMATRYX BIOPHARMA S.A.
- Website
- https://oncomatryx.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Oncomatryx is a Spain-based clinical-stage biopharmaceutical company developing antibody-drug conjugates that target Cancer-Associated Fibroblasts in the tumor microenvironment, with lead candidate OMTX705 in Phase Ib/2 trials for metastatic solid tumors.
- Ownership category
- akta.pro rank
Oncomatryx industry classification
Industry- Product category
- Oncology Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Oncology & Hematology Pharmaceuticals (HLAIAAAC)
Keywords
Where Oncomatryx is headquartered
LocationHeadquarters
- HQ city
- Derio
- HQ country
- Spain
- HQ region
- Europe
Offices4 records
Markets served
Oncomatryx business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Licensing Agreements: Oncomatryx generates recurring revenues from licensing agreements with international biopharmaceutical companies. The company licenses its technology and drug candidates to larger pharmaceutical partners.
- Strategic Co-development Partnerships: Partnerships with pharmaceutical companies for co-development of ADC candidates, including funding contributions and milestone payments.
- EIC Accelerator Funding: Non-dilutive funding from European Innovation Council: €2.5 million grant plus €10 million equity investment in upcoming financing round.
- Future Drug Commercialization: Plans to commercialize approved drug candidates upon successful clinical trials and regulatory approval.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
Oncomatryx product offering
Product offeringCore offering
Oncomatryx develops antibody-drug conjugates (ADCs) that target the tumor microenvironment—specifically Cancer-Associated Fibroblasts (CAFs)—rather than tumor cells directly. Its lead candidate OMTX705 (anti-FAP ADC) is in Phase 1/2 trials for metastatic solid tumors (pancreatic, colorectal, lung, sarcomas), supported by preclinical assets OMTX703 and OMTX707 and companion diagnostic tools such as InvaScan. Revenue is generated through licensing/co-development with biopharmaceutical partners, with future commercialization planned post-approval.
Product overview
Oncomatryx is a clinical-stage biopharmaceutical company pioneering Quantum Immunotherapy through a proprietary ADC (Antibody-Drug Conjugate) platform. The company's portfolio centers on three ADC candidates—OMTX705 (Phase 1/2, anti-FAP for multiple solid tumors), OMTX703 (preclinical, anti-endoglin for gastric cancer and sarcomas), and OMTX707 (preclinical, tumor microenvironment-targeting)—alongside companion diagnostic products including InvaScan for detecting COL11A1 in invasive tumors. The integrated platform combines selective tumor microenvironment-targeting antibodies with synthetic cytolysin payloads and stable conjugation technology. The company also operates AI-driven research programs including IA-CLINIC for automated clinical reports and 3DTRYX for 3D biological systems.
Differentiator
Problem solved
Functional benefit
Brands
- InvaScan (DMTXinvaScan): Immunohistochemical tissue staining system for diagnosis and prognosis of invasive tumors using monoclonal antibody detecting Collagen XI-α1
- OMTX705
- OMTX703
- OMTX707
- Quantum ADCs
Products and services
- OMTX705 First-in-class anti-FAP (Fibroblast Activation Protein) antibody-drug conjugate targeting cancer-associated fibroblasts in the tumor microenvironment. In Phase 1/2 clinical trials for pancreatic cancer (PDAC), microsatellite-stable colorectal cancer (MSS-CRC), non-small cell lung cancer, and sarcomas.
- OMTX703 Anti-endoglin (ENG) antibody-drug conjugate in preclinical development for the treatment of gastric cancer, Ewing sarcoma, and uveal melanoma.
- OMTX707 ADC product candidate targeting the tumor microenvironment (TME:CYT), in development for the treatment of sarcomas and fibrosis.
- InvaScan (DMTX Invascan) Immunohistochemistry-based companion diagnostic for detecting Collagen XI-α1 (COL11A1) in tissue biopsy samples to diagnose and prognose invasive tumors including colon, pancreatic, kidney, breast, ovarian, head and neck, lung, and bladder cancers.
Quantifiable outcome
- 100% tumor growth inhibition and complete regression in PDX models of pancreatic, gastric, ovarian, triple-negative breast, and lung cancers
- +3 more outcomes
Companies that use Oncomatryx
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Oncomatryx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature4 records
Oncomatryx partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- Tube Pharmaceuticals GmbHcoreAcquired Tube Pharmaceuticals GmbH for multimillion euros, consolidating decade-long alliance. Acquired Cytolysin toxic payload portfolio and cutting-edge technology. Dr. Wolfgang Richter joined Oncomatryx to lead chemistry efforts. Tube had 15+ years experience in novel ADC payload generation.
- University of StuttgartminorEuropean academic collaboration in ADC development. Professor Roland E. Kontermann (Subdirector, Institute of Biomedical Engineering) serves on Scientific Advisory Board.
- University of TorinominorEuropean academic collaboration. Professor Franco Dosio (Emeritus, Department of Pharmaceutical Sciences) serves on Scientific Advisory Board.
- CIC-BioguneminorCollaboration with Basque biomedical research center for cancer research and ADC development.
- CNIO (Centro Nacional de Investigaciones Oncológicas)minorCollaboration with Spanish National Cancer Research Center for oncology research.
- Harvard UniversityminorUS academic collaboration in ADC research and development.
- MD Anderson Cancer CenterminorCollaboration with leading US cancer center for ADC clinical development.
- Hospitals in Spain and USA (Clinical Trial Sites)coreSeven hospitals conducting Phase 1 clinical trials for OMTX705 in Spain and USA. Onkologikoa (Osakidetza) participating under Basque Government collaboration.
Scale indicators8 records
Recent moves7 records
Expansion highlights6 records
Oncomatryx competitors and assessment
Company assessmentDirect peers
- Heidelberg Pharma: German clinical-stage biotech developing ADCs with proprietary amanitin payloads, analogous to Oncomatryx's novel payload approach with cytolysins. Both are European ADC platform companies with proprietary payload technologies and lead assets in Phase 1/2 oncology trials.
- ADC Therapeutics: Clinical-stage ADC company developing pyrrolobenzodiazepine-based antibody-drug conjugates for hematologic and solid tumors. Directly comparable as a focused ADC pure-play with multiple clinical-stage assets and platform payload conjugation technology.
- Mersana Therapeutics: Clinical-stage ADC company with proprietary Dolasynthen and Immunosynthen platforms targeting oncology. Comparable as an ADC-focused biotech developing differentiated linker/payload systems against solid tumor indications.
Broad incumbents
- ImmunoGen (AbbVie): Pioneer in ADC technology with multiple approved and clinical-stage assets including ELAHERE (mirvetuximab), now part of AbbVie. Comparable as an ADC-focused oncology company with proprietary maytansinoid payload and conjugation chemistry used in solid tumor indications.
- Daiichi Sankyo: Japanese pharmaceutical leader behind the DXd ADC technology platform used in Enhertu and Datroway, with extensive ADC pipeline in oncology. Comparable as an established ADC innovator targeting solid tumors with proprietary payload and conjugation technology.
- Pfizer (Seagen): Major pharmaceutical company with the Seagen-acquired ADC platform producing approved ADCs like Adcetris and Padcev. Comparable as an established ADC player with proprietary payload technology and multiple oncology programs.
Emerging players
- Pyxis Oncology: Clinical-stage ADC and immuno-oncology biotech with multiple ADC candidates in early-stage trials for solid tumors. Comparable as an emerging ADC company with platform technology focused on tumor-microenvironment and immune-related targets.
- CytomX Therapeutics: Clinical-stage biotech developing conditionally activated Probody ADCs and other masked therapeutics for oncology. Comparable as an emerging ADC platform company with multiple solid tumor candidates in early clinical development.
- Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing ADCs with immune-stimulating Boltbody technology. Comparable as an emerging ADC platform company combining tumor targeting with immune stimulation for solid tumors.
- Oxford BioTherapeutics: Clinical-stage biotech developing ADCs and immuno-oncology therapeutics for solid tumors, with strategic partnerships with major pharma. Comparable as a European-headquartered ADC company with platform technology targeting multiple solid tumor indications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Oncomatryx social profiles
Digital presenceOncomatryx financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oncomatryx leadership team
Management profileNumber of profiles
Profiles6 records
Oncomatryx subsidiaries and ownership
Company hierarchySubsidiaries3 records
Oncomatryx funding detail
Funding detailFunding overview
Funding rounds6 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oncomatryx M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oncomatryx
What does Oncomatryx do?
Oncomatryx develops antibody-drug conjugates (ADCs) that target the tumor microenvironment—specifically Cancer-Associated Fibroblasts (CAFs)—rather than tumor cells directly. Its lead candidate OMTX705 (anti-FAP ADC) is in Phase 1/2 trials for metastatic solid tumors (pancreatic, colorectal, lung, sarcomas), supported by preclinical assets OMTX703 and OMTX707 and companion diagnostic tools such as InvaScan. Revenue is generated through licensing/co-development with biopharmaceutical partners, with future commercialization planned post-approval.
Is Oncomatryx a public or private company?
Oncomatryx is a private company. It is classified as venture growth investor backed and is currently operating.
When was Oncomatryx founded?
Oncomatryx was founded in 2010. It employs 11 to 50 people.
Where is Oncomatryx based?
Oncomatryx is headquartered in Derio, Spain, in the Europe region.
How does Oncomatryx make money?
Four revenue lines are on record. Licensing Agreements are the primary driver. The others are strategic Co-development Partnerships, EIC Accelerator Funding and future Drug Commercialization.
Who are Oncomatryx's main competitors?
Direct peers on record are Heidelberg Pharma, ADC Therapeutics and Mersana Therapeutics. Broad incumbents are ImmunoGen (AbbVie), Daiichi Sankyo and Pfizer (Seagen). Emerging players are Pyxis Oncology, CytomX Therapeutics, Bolt Biotherapeutics and Oxford BioTherapeutics.
Does Oncomatryx have an API?
No public API is recorded for Oncomatryx.
What industry is Oncomatryx in?
Oncomatryx's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2836.